Cell Therapy

Oncology

Partner Content

CAR:T - Has biology outpaced the ability to deliver?

CAR-T, the latest development in research is catapulting cell therapy to the headlines.

News

Astellas teams up with UK biotech Mogrify on hearing loss pr...

Cell therapy specialist Mogrify has struck a deal with Japanese drugmaker Astellas to look at ways to deploy regenerative medicine to treat hearing loss caused by factors such as chronic ex

News

Kymriah is first CAR-T cleared for follicular lymphoma in EU

Novartis' CAR-T Kymriah has become the first therapy in the category to be approved for the treatment of relapsed/refractory follicular lymphoma, ahead of Gilead Sciences' rival Yescarta.

News

Nkarta leaps on early CAR-NK data in blood cancers

Shares in Nkarta more than doubled yesterday on the results of early-stage clinical that suggested it could be on to a winner with its natural kill (NK) cell therapy platform.

Events

Partner Content

3rd Gamma Delta T Therapies Summit

The Only Industry-Specific Event on γδT Therapies

News

Bayer backs KRAS TCR player Affini-T in $175m financing

Bayer's venture capital unit has co-led a $175 million investment in Affini-T that will be used to take its T cell receptor (TCR) therapies for cancer cells with mutations like KRAs and p53

CAR:T - Has biology outpaced the ability to deliver?

Astellas teams up with UK biotech Mogrify on hearing loss pr...

Kymriah is first CAR-T cleared for follicular lymphoma in EU

Nkarta leaps on early CAR-NK data in blood cancers

3rd Gamma Delta T Therapies Summit

Bayer backs KRAS TCR player Affini-T in $175m financing

OpenBind unveils its first AI model for drug discovery

Discover a new era of healthcare panel engagement: Grounded ...

Cell Therapy

Editor's Picks